---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000078"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:27:21.791962+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE

## Summary
- CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.
- CFO Renee Barnett stepped down; Tiago Girao appointed CFO with $481K salary and $6.66M equity award.
- Board changes: George Migausky resigned; Robert Susman and Jacob Bauer appointed as directors.
- IMVT-1402 IND cleared for potential registrational study in Sjögren's disease, start summer 2025.
- Proof-of-concept study in Cutaneous Lupus Erythematosus initiated; cash runway through Graves' readout in 2027.

## SEC filing metadata
- accession: 0001764013-25-000078
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/imvt-20250418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000078
- JSON: https://secwatch.observer/filing/0001764013-25-000078.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000078.txt

## Key facts
- Executive change
  Peter Salzmann retired as Member of Board of Directors at Immunovant, Inc..
  - Action: retired
  - Role: Member of Board of Directors
  source text: and as a member of the Company’s Board of Directors (the “Board”), effective April 18, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- Executive change
  Robert Susman was appointed as Member of Board of Directors at Immunovant, Inc..
  - Action: appointed
  - Role: Member of Board of Directors
  source text: the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- Executive change
  Jacob Bauer was appointed as Member of Board of Directors at Immunovant, Inc..
  - Action: appointed
  - Role: Member of Board of Directors
  source text: the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- Executive change
  Peter Salzmann retired as Chief Executive Officer at Immunovant, Inc..
  - Action: retired
  - Role: Chief Executive Officer
  source text: Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the "Company" or "Immunovant"), effective April 20, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- Executive change
  George Migausky resigned as Member of Board of Directors at Immunovant, Inc..
  - Action: resigned
  - Role: Member of Board of Directors
  source text: On April 18, 2025, George Migausky, a member of Immunovant’s Board and Chair of the Audit Committee of the Board (the “Audit Committee”), resigned from the Board and the Audit Committee, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm
- Executive change
  Renee Barnett departed as Chief Financial Officer at Immunovant, Inc..
  - Action: ceased serving
  - Role: Chief Financial Officer
  source text: Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/0001764013-25-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.